Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HB0025 plus nab-paclitaxel as first-line treatment for unresectable locally advanced, recurrent, or metastatic triple-negative breast cancer
CTR20251978Phase 2Active
- Sponsor
- Huabo Biopharm
- Start
- Aug 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of sotiburafusp alfa in triple-negative breast cancer (TNBC), sponsored by Huabo Biopharm. Started Aug 2025; status: active.
02
Drugs
sotiburafusp alfa
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20251978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251978.